Ultrahuman’s Financials, Revenue, Profit, Valuation & Shareholding Overview (2025)
Legal Name: Ultrahuman Healthcare Private Limited | CIN: U74999KA2019PTC129250
Ultrahuman, founded in 2019, is a pioneering health and wellness technology company based in Bengaluru, India. Co-founded by Vatsal Singhal and Mohit Kumar, Ultrahuman empowers individuals to optimize metabolic health through its innovative wearable devices and personalized insights. The company’s flagship continuous glucose monitoring platform, Ultrahuman M1, along with other metabolic fitness products, help users understand their body's responses and make informed lifestyle decisions. By combining advanced biosensing technology with intuitive data visualization, Ultrahuman aims to transform preventive health and performance optimization on a global scale. Its vision is to create a world with better metabolic health, reduced lifestyle diseases, and improved longevity.
| Founded | 2019 |
|---|---|
| Headquarters | Bengaluru, India |
| Sector | HealthTech & Wellness |
| Revenue FY23 | $12.9 million |
| Profit/Loss FY23 | -$6 million |
| Employees (approx.) | 300 |
| Round | Date | Amount (USD) | Valuation (USD) | Investors |
|---|---|---|---|---|
| Series B | Mar 21, 2024 | $25M | — | Steadview Capital, Nexus Venture Partners |
| Series A | Mar 08, 2022 | $4.6M | — | Alpha Wave Incubation, Blume Ventures |
| Series A | Aug 17, 2021 | $17.5M | — | Steadview Capital, Nexus Venture Partners, Blume Ventures |
| Seed | Dec 17, 2019 | $7.8M | — | Blume Ventures, WEH Ventures |
Ultrahuman has witnessed robust revenue growth, increasing from $5 million in FY22 to an expected $20 million in FY24. While the company continues to operate at a loss due to high R&D and expansion expenses, losses have narrowed steadily, indicating stronger financial health and operational efficiency gains.
Ultrahuman has strategically increased its expenses to scale globally and invest in advanced technologies. Despite higher operational costs, the company is focused on margin improvement and expects profitability as economies of scale and subscription revenues expand further.
Ultrahuman has significantly expanded its team from 200 employees in FY22 to an estimated 400 by FY24. This growth aligns with its international expansion plans and ongoing product innovations, reinforcing its position as a leader in metabolic health technology.
| Metric | Detail |
|---|---|
| Revenue FY23 | $12.9 million |
| Profit/Loss FY23 | -$6 million |
| Funding Raised | $54.9 million total |
| Employees | 300+ and expanding |
Ultrahuman demonstrates strong revenue growth and an expanding workforce, reflecting investor confidence and product-market fit. Continued focus on technological innovation and operational improvements positions the company well for future profitability and market leadership.
Ultrahuman is redefining health and wellness with its pioneering wearable technology and data-driven insights. The company’s impressive growth trajectory, strong investor support, and commitment to innovation make it a standout player in the healthtech space. Make smarter business decisions with verified insights on companies and directors. Visit Affluense.ai to learn more.
- Company filings and reports
- Public news articles
- Affluense.ai research
© 2025. All information is curated from public and third-party sources and provided solely for legitimate business use. Please ensure proper authorization before use. The depth of information depends on what is publicly available and may vary between individuals.